









Markets
/
Stocks
/
nasdaq-edsa
/

Edesa Biotech Inc

EDSA

1.120USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

8.00MMarket Cap

LossP/E TTM



Edesa Biotech Inc

1.120

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Edesa Biotech Inc

Currency: USD Updated: 2026-02-06

Key Insights

Edesa Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 137 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Edesa Biotech Inc's Score

Industry at a Glance

Industry Ranking

137 / 392

Overall Ranking

281 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Edesa Biotech Inc Highlights

StrengthsRisks

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

Fairly Valued

The company’s latest PE is -0.88, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 37.60K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.000

Target Price

+882.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Edesa Biotech Inc is 6.94, ranking 182 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.94

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Edesa Biotech Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Edesa Biotech Inc is 6.60, ranking 250 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.88, which is -85.95% below the recent high of -0.12 and -248.77% above the recent low of -3.09.

Score

Industry at a Glance

Previous score

6.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 137/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Edesa Biotech Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 19.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.000

Target Price

+882.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Edesa Biotech Inc

EDSA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Edesa Biotech Inc is 6.35, ranking 262 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.48 and the support level at 0.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.36

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.047

Sell

RSI(14)

29.453

Sell

STOCH(KDJ)(9,3,3)

31.881

Neutral

ATR(14)

0.120

High Vlolatility

CCI(14)

-92.994

Neutral

Williams %R

70.035

Sell

TRIX(12,20)

-0.987

Sell

StochRSI(14)

52.443

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.140

Sell

MA10

1.226

Sell

MA20

1.344

Sell

MA50

1.487

Sell

MA100

1.865

Sell

MA200

2.026

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Edesa Biotech Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 32.19%, representing a quarter-over-quarter decrease of 0.42%. The largest institutional shareholder is The Vanguard, holding a total of 37.60K shares, representing 0.45% of shares outstanding, with 99.73% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Nijhawan (Pardeep)

787.97K

-35.85%

Rubric Capital Management LP

687.50K

Velan Capital Investment Management LP

687.50K

Stonepine Capital Management, LLC

687.50K

Nantahala Capital Management, LLC

625.00K

Pardeep Nijhawan Medicine Professional Corporation

341.70K

-5.24%

Brooks (Michael J Ph.D.)

95.41K

-57.57%

Marshall (Patrick)

49.47K

-6.90%

Geode Capital Management, L.L.C.

45.23K

+61.80%

The Vanguard Group, Inc.

Star Investors

45.54K

+187.08%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Edesa Biotech Inc is 2.19, ranking 247 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.21. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.